Income Statement
GRACE THERAPEUTICS, INC.
GRCE
Performance Overview
Click any row in the table to add it to this chart
in millions USD
| Metric | Mar 31, 2025 2024 FY | Mar 31, 2024 2023 FY | Mar 31, 2023 2022 FY | Mar 31, 2022 2021 FY | Mar 31, 2021 2020 FY | Mar 31, 2020 2019 FY |
|---|---|---|---|---|---|---|
|
Revenue
|
- | - | - | - | - | - |
|
Cost of Revenue
|
- | - | - | 0.00 | 0.08 | - |
|
Gross Profit
|
- | - | - | - | -0.08 | - |
|
Operating Expenses
|
35.06 | 11.12 | 17.59 | 14.82 | 9.69 | 21.77 |
|
Research & Development
|
27.89 | 4.68 | 9.97 | 5.56 | 4.17 | 15.97 |
|
Selling, General & Administrative
|
7.17 | 6.43 | 7.61 | 9.26 | 5.52 | 5.80 |
|
Other Operating Expenses
|
- | - | - | - | - | - |
|
Operating Income
|
-35.06 | -11.12 | -17.59 | -14.82 | -9.77 | -21.77 |
|
Non-Operating Income
|
3.91 | -1.83 | 0.18 | 5.12 | -3.26 | -1.08 |
|
Interest Income
|
0.71 | 0.91 | 0.25 | 0.08 | 0.11 | 0.34 |
|
Interest Expense
|
- | - | - | - | - | - |
|
Other Non-Op Income / Expense
|
- | - | - | - | - | - |
|
Income Before Tax
|
-12.77 | -14.69 | -51.97 | -10.47 | -19.68 | -25.51 |
|
Income Tax Expense
|
-3.20 | -1.83 | -9.54 | -0.65 | - | - |
|
Non-Controlling Interest
|
- | - | - | - | - | - |
|
Net Income
|
-9.57 | -12.85 | -42.43 | -9.82 | 19.68 | 25.51 |
Supplemental
Per share data, derived & other items — not part of the income statement
in millions USD unless noted
| Metric | Mar 31, 2025 2024 FY | Mar 31, 2024 2023 FY | Mar 31, 2023 2022 FY | Mar 31, 2022 2021 FY | Mar 31, 2021 2020 FY | Mar 31, 2020 2019 FY |
|---|---|---|---|---|---|---|
|
Depreciation & Amortization
|
- | - | - | - | - | - |
|
EBITDA
|
-35.06 | -11.12 | -17.59 | -14.82 | -9.77 | -21.77 |
|
Earnings Per Share (Basic)
|
-0.79 | -1.35 | -0.95 | - | - | - |
|
Diluted EPS
|
-0.79 | -1.35 | -0.95 | - | - | - |
|
Weighted Average Shares
|
12.09 | 9.53 | 44.61 | - | - | - |
|
Diluted Weighted Avg Shares
|
12.09 | 9.53 | 44.61 | - | - | - |
|
Comprehensive Income
|
-9.57 | - | - | - | - | - |